key: cord-0849714-rhtpajoq
authors: Huang, Zhen; Tian, Di; Liu, Yang; Lin, Zhen; Lyon, Christopher; Lai, Weihua; Fusco, Dahlene; Drouin, Arnaud; Yin, Xiaoming; Hu, Tony; Ning, Bo
title: Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis
date: 2020-05-23
journal: Biosens Bioelectron
DOI: 10.1016/j.bios.2020.112316
sha: c8e9fe46a5fe98d7cd224f08cfe79dc5ec518380
doc_id: 849714
cord_uid: rhtpajoq

Recent research suggests that SARS-CoV-2-infected individuals can be highly infectious while asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on average. This situation highlights the need for rapid, sensitive SARS-CoV-2 diagnostic assays capable of high-throughput operation that can preferably utilize existing equipment to facilitate broad, large-scale screening efforts. We have developed a CRISPR-based assay that can meet all these criteria. This assay utilizes a custom CRISPR Cas12a/gRNA complex and a fluorescent probe to amplify target amplicons produced by standard RT-PCR or isothermal recombinase polymerase amplification (RPA), to allow sensitive detection at sites not equipped with real-time PCR systems required for qPCR diagnostics. We found this approach allowed sensitive and robust detection of SARS-CoV-2 positive samples, with a sample-to-answer time of ∼50 min, and a limit of detection of 2 copies per sample. CRISPR assay diagnostic results obtained nasal swab samples of individuals with suspected COVID-19 cases were comparable to paired results from a CDC-approved qPCR assay performed in a state testing lab, and superior to those produced by same assay in a clinical lab, where the qPCR assay exhibited multiple invalid or inconclusive results. Our assay also demonstrated greater analytical sensitivity and more robust diagnostic performance than other recently reported CRISPR-based assays. Based on these findings, we believe that a CRISPR-based fluorescent application has potential to improve current COVID-19 screening efforts.

Recent research suggests that SARS-CoV-2-infected individuals can be highly infectious while 23 asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals 24 on average. This situation highlights the need for rapid, sensitive SARS-CoV-2 diagnostic assays 25 capable of high-throughput operation that can preferably utilize existing equipment to facilitate 26 broad, large-scale screening efforts. We have developed a CRISPR-based assay that can meet all 27 these criteria. This assay utilizes a custom CRISPR Cas12a/gRNA complex and a fluorescent 28 probe to amplify target amplicons produced by standard RT-PCR or isothermal recombinase 29 polymerase amplification (RPA), to allow sensitive detection at sites not equipped with real-time 30 PCR systems required for qPCR diagnostics. We found this approach allowed sensitive and 31 robust detection of SARS-CoV-2 positive samples, with a sample-to-answer time of ~ 50 min, 32 and a limit of detection of 2 copies per sample. CRISPR assay diagnostic results obtained nasal 33 swab samples of individuals with suspected COVID-19 cases were comparable to paired results 34 from a CDC-approved qPCR assay performed in a state testing lab, and superior to those 35 produced by same assay in a clinical lab, where the qPCR assay exhibited multiple invalid or 36 inconclusive results. Our assay also demonstrated greater analytical sensitivity and more robust 37

SARS-CoV-2, first detected in China's Hubei province late in 2019, rapidly spread from its 45 initial outbreak site to produce a pandemic (Zhou et al. 2020), and has to date been detected in 46 more than 200 countries, where it has infected more than 1.9 million people and caused more 47 than 116,000 deaths (Liu et al. 2020a). However, disease control efforts are hindered by multiple 48 factors, including difficulty in rapidly producing the number diagnostic tests required for such 49 efforts, the apparent limited diagnostic sensitivity of current tests, and the technical expertise 50 required to obtain valid results with them. Large scale testing appears to be essential since 51 estimates indicate that large numbers of mild, asymptomatic or pre-symptomatic COVID-19 52 cases are not detected by current testing efforts (Kobayashi et al. 2020 In this work, we describe a rapid and accurate RT-PCR CRISPR-Cas12a fluorescent reporter 103 assay that demonstrates comparable diagnostic performance to a CDC-approved test performed 104 in a state testing lab, without inconclusive or invalid results that observed when the same 105 QIAGEN (Hilden, Germany). The SuperScript™ IV One-Step RT-PCR System (#1235820), 113

TaqPath TM 1-Step RT-qPCR Master Mix (4X) (#A15299), nuclease-free water (#4387936), and 114 carrier RNA (#4382878) work as negative control was purchased from Thermo Fisher Scientific 

A total of 29 nasal swab specimens were collected based on clinical indications and current CDC 126 guidance from Tulane Hospitals in New Orleans, LA from April 1 to April 10, 2020. 127

Subsequently, 100 µL of RNA were extracted from equal volumes of clinical sample using the 128

QIAamp DSP Viral RNA Mini Kit, and extracted RNA was stored at -80°C until analysis 129

For RT-PCR reactions, 5 µL isolated RNA sample was mixed with 15 µL of one-step RT-PCR 131 mix containing 10 µL of 2X Platinum TM SuperFi TM RT-PCR Master Mix, 1 µL of forward 132 primer (10 µM), 1 µL of reverse primer (10 µM), 0.2 µL of SuperScript TM IV RT Mix, and 2.8 followed by a DNA amplification protocol (98°C for 2 min; 35 cycles at 98°C for 10 s, 60°C for 136 10 s, and 72°C for 15 s, followed by a final elongation step at 72°C for 5 min). RPA pellets were 137 resuspended in 29.5 µL of the supplied Rehydration Buffer, and 11.8 µL of this RPA solution, For the Cas12a substrate-dependent kinetics study, the system was conducted with the molar 149 ratio of Cas12a/gRNA to fluorescent probe at 1:5, 1:10, 1:15, 1:20, and 1:25. For the 150 temperature-dependent kinetics study, reactions were performed using a 1:20 Cas12a/gRNA to 151 fluorescent probe ratio at 27°C, 37°C, and 42°C. For target-dependent of kinetics study, the 152 system was conducted with reactions were performed using a 1:20 Cas12a/gRNA to fluorescent 153 probe ratio and 10 6 ,10 7 , 10 8 , 10 9 and 10 10 copies of the target fragments. 154

of nuclease-free water. RT-qPCR reactions were performed using a QuantStudio 6 Flex 159

Real-Time PCR System (Thermo Fisher Scientific Inc., Waltham, USA) using the reaction 160 conditions specified for this assay. For CRISPR-FDS assays, samples were processed as 161 described in Section 2.4, using a 1:20 molar ratio of Cas12a/gRNA to fluorescent reporter and 162

analyzed after incubation at 37 °C for 20 min. 163 3 Results 164

RT-qPCR is the most popular method employed for SARS-CoV-2 detection, but requires 167 significant technical expertise, as well as equipment that is not available in all clinical 168 laboratories. The COVID-19 CRISPR-FDS we describe is uses a streamlined approach that does 169 not require any special equipment beyond that found in most clinical and research laboratories. Figure 1F) . 214

Since the CRISPR-FDS determines the sensitivity of this assay, we conducted systematic studies 216 of its reaction kinetics to optimize assay performance. CRISPR-mediated photoluminescence 217 (PL) signal progressively increased with input fluorescent reporter substrate concentration, when 218 CRISPR-FPR assays containing a constant amount of target RNA were incubated with 219 increasing amounts of substrate (Figure 2A) . Signal-to-noise ratio increased with the ratio of 220 reporter substrate to CRISPR/gRNA complex in this analysis, demonstrating the greatest 221 signal-to-noise ratio at a 1:20 molar ratio of Cas12a/gRNA to reporter and plateauing or 222 modestly decreasing at a 1:25 ratio, the highest analyzed in this study. A potential decrease 223 detected at the highest reporter concentration could be due to the background fluorescent signal 224 of un-cleaved reporter. Given the benefits of high signal-to-noise ratio for assay sensitivity, we 225 elected to use the 1:20 ratio for subsequent experiments. The final CRISPR-FDS signal intensity did not differ with temperature in assays incubated at 27°C to 42°C, but incubation temperature significantly altered the rate of substrate conversion, with reaction completion times decreasing 228 from 30 minutes at 27°C, to 14 and 12 minutes at 37°C and 42°C, respectively ( Figure 2B) . which was 5 copies/test (Figure 3C) . Signals of complete CRISPR-FDS reactions were also 245 found to be stable for ≤ 1 hour at ambient temperature, reducing the need to read signal quickly 246 when testing large sample batches.

positive if it was equal or greater than a cut-off threshold equal to the mean signal of the negative 250 control samples plus three times its standard deviation (Kim et al. 2016) . Using this criterion, 19 251 of 29 nasal swab samples were found to be SARS-CoV-2 positive (Figure 3D) . These results 252 demonstrated good overall agreement with valid and conclusive test results from the state and 253 hospital laboratories that were generated using a CDC-authorized qPCR method (Figure 3E) . 254

These patients were diagnosed based on the results from the state testing laboratory (qPCR 1), 255

considering the poor quality of the hospital laboratories results. CRISPR-FDS exhibited 256 complete concordance with the positive results obtained by the state testing laboratory (100% 257 sensitivity), detected SARS-CoV-2 signal in three samples (1, 5 and 6) that were judged to be 258 negative by the state testing laboratory (71.4% specificity). In the absence of serology data or 259 other information, it is not clear if these three samples represent false positive CRISPR-FDS 260 assay results, or if they represent positive samples that were missed by the qPCR method. 261

Notably, 10 of the samples analyzed by the hospital did produce valid results and two others had 262 inconclusive results, which compared poorly with the result rate from the state lab, and suggest 263 the difficulty of introducing this assay in a hospital setting, particularly during an emerging 264 epidemic. 265

Although qRT-PCR is the most widely used diagnostic method for COVID-19, its sensitivity has 267 not proven satisfactory, resulting in a relatively high number of false-negative results so that a 268 substantial number of infected individuals do not receive proper diagnoses and treatment. In a 269 study of more than 1,000 patients, 75% COVID-19 suspects had negative qRT-PCR test results 270 but positive chest CT results, and 48% of these patients were considered highly likely to have but many problems were found in the detailed analysis of this method, such as low sensitivity 281 and low throughput. Our attempt to replicate results from one of the LAMP studies found that 282 the described N gene and E gene LAMP reactions exhibited strong non-specific amplification, 283 and that it was not possible to distinguish between positive and negative samples, even after 284 titrating the amount input template or varying the reaction time or temperature ( Figure S1 ). We 285 therefor did not pursue RT-LAMP as a potential means for template amplification in our 286 CRISPR-FDS assay. Further, while we found that RPA worked well, we did not employ it in our 287 final assay, since the necessary reagents are currently available from a single company, limiting 288 its potential for immediate widespread application. 289

Many CRISPR protocols use paper strips to detect the signal output. This is a good solution for 290 single sample testing since it does not require any equipment to read the results, but its LOD is 291 much lower than fluorescence-based detection methods (Table S3 ). Our CRISPR-FDS assay can 292 be readily performed in 96-well microtiter plates and read with fluorescent plate readers found in detection. Finally, our results indicate that our CRISPR-FDS demonstrates results comparable to 295 those obtained with a CDC-approved qPCR assay in a state testing lab, but produced more valid 296 results than were obtained when the same qPCR assay was employed in a clinical setting. 297

Notably, CRISPR-FDS produced positive results for a fraction of the samples that produced 298

negative results with the qPCR assay, although it was not possible to determine if these results 299

represented false positive CRISPR-FDS results or false negative qPCR results due to the lack of 300 associated follow up data. CRISPR-FDS thus produces sensitive and robust results using readily 301 available equipment and streamlined, high-throughput workflow suitable for use in clinical 302 laboratories, and potentially applicable to point of care settings with the appropriate equipment. 303

One drawback potential drawback to our CRISPR-FDS approach is that is designed to provide 304 clear positive or negative results, but to quantify viral load, as can be determined by qPCR assays 305 using real-time PCR systems. We do not see this as a major drawback given the clear need for 306 rapid, sensitive, and robust assays to diagnose COVID-19. 307

RT-PCR or RT-RPA CRISPR-based detection methods provide a sensitive and robust means for 309 high-throughput COVID-19 diagnosis suitable for use in clinical laboratories, and exhibit the 310 potential to enable reliable COVID-19 diagnosis at remote testing sites with minimal equipment, 311

to improve large scale diagnosis efforts required to reduce the SARS-CoV-2 transmission and 312 COVID-19 disease. However, further efforts need to be made to overcome the current bottleneck 313 in point of care testing to permit self-testing or increase the testing capacity of small clinics that 314 lack the resources to perform current assays. We are currently investigating the potential to 315 integrate the RT-RPA-based CRISPR-FDS onto a microfluidic chip that can be read by a smart point-of-care diagnostics: a critical review. Lab Chip 12(14), 2469-2486. 341

Ding, X., Yin, K., Li, Z., Liu, C., 2020. All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) (qPCR 1) and a clinical testing laboratory (qPCR 2). (ns, P>0.05; *, P < 0.05; **, P < 0.01; ***, 462

SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients

Five-minute point-of-care testing for SARS-CoV-2: Not there yet

Homogeneous Entropy-Driven Amplified 369 Detection of Biomolecular Interactions

Communicating the 372 Risk of Death from Novel Coronavirus Disease (COVID-19)

CRISPR-Cas12a-assisted nucleic acid detection

CRISPR/Cas Systems towards Next-Generation

Genomic characterisation and epidemiology of 386 2019 novel coronavirus: implications for virus origins and receptor binding

An ultrasensitive, rapid, and portable 389 coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12

Estimating the asymptomatic 391 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise 392 ship

Loop-mediated isothermal amplification of DNA

Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular 398

Comparison of Cepheid

Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2

Diagnosing COVID-19: The Disease and 407 Tools for Detection

Isothermal reactions for the amplification of 409 oligonucleotides

Average detection rate of SARS-CoV-2 infections is estimated around 411 six percent University of Goettingen

Real-time PCR for mRNA quantitation

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using 416

Rapid 418 colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated 419 isothermal amplification (RT-LAMP)

Recombinase polymerase amplification as a promising tool in 421 hepatitis C virus diagnosis

SARS-CoV-2 Viral Load in Upper 429

Respiratory Specimens of Infected Patients

RT-PCR for related beta coronavirus species (10 9 copies/sample). Bar graph 441 data represents the mean ± SD

Integrated CRISPR for COVID-19 clinical diagnosis 2. Rapidly identify SARS-CoV-2-specific RNA signatures at an ultra-low concentration